Wojciech Jurczak, MD, PhD, discusses advancements in B-cell lymphoma therapy, focusing on immunotherapy, molecular-targeted agents, and more.

A study of 200 patients with chronic lymphocytic leukemia (CLL) showed a lower rate of severe and serious adverse events ...

Harrington Prize for Innovation in Medicine has been awarded to Owen N. Witte, MD, Distinguished University Professor and President's Chair in Developmental Immunology, David Geffen School of Medicine ...

Bexobrutideg, a first-in-class Bruton’s tyrosine kinase degrader, has been granted orphan drug designation from the FDA in ...

Fintel reports that on March 17, 2025, Leerink Partners initiated coverage of Nurix Therapeutics (NasdaqGM:NRIX) with a ...

Orphan Drug Designation follows positive Phase 1 data presented at the 12th International Workshop on Waldenström ...

National MS Education and Awareness Month is celebrated each year in the US in March, after having been launched in 2003 by ...

BREYANZI has significant market potential due to its innovative approach as a CD19-directed chimeric antigen receptor (CAR) T-cell therapy. The growing prevalence of hematologic malignancies ...

For patients with symptomatic chronic spontaneous urticaria after treatment with second-generation H 1-antihistamines, ...

Bruton’s boys captured the Class 2 indoor track and field championship Thursday at Liberty University in Lynchburg, outpointing runner-up Stuarts Draft 80-76. The Panthers led by two points ...

particularly focusing on Bruton tyrosine kinase (BTK) inhibitors such as tolebrutinib. A new post hoc analysis data demonstrated that tolebrutinib mitigated the risk for disability worsening in ...